What's breaking now, across thousands of outlets.
Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story was originally published by Vox and is reproduced here as part of the Climate Desk collaboration. Summer is supposed to be the best time for fresh produce. Corn on the cob at the cookout.
The partnership will bring Noom Weight, Diabetes Prevention Program and a no-cost GLP-1 companion to Solera Health members
Duale said the government’s response must go beyond keeping people with sickle cell disease alive. The post Kenya steps up efforts to improve sickle cell care appeared first on KBC Digital .
